Uric Acid pp 525-555 | Cite as

Pharmacology of Drugs Used in Treatment of Acute Gout

  • S. L. Wallace
  • N. H. Ertel
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 51)


Once the diagnosis of acute gout is made, treatment is generally simple and straightforward. Acute gout is probably the most easily treated of the arthritides, provided that therapy is begun early. Most agents effective in controlling acute gouty inflammation have been in use for years and are well known; several new agents have recently become available (Wallace, 1975). A number of reports on the treatment of acute gout have been published (Goldfinger, 1971; Wallace, 1972; Wyngaarden and Kelley, 1976). Table 1 lists the major drugs that have been used for this purpose in clinical practice. The pharmacology and mechanisms of action of these drugs are less well appreciated, however, and deserve further emphasis, although a series of reviews of the clinical pharmacology of one of these agents, colchicine, has previously been reported (Wallace, 1961, 1965; Wallace and Ertel, 1969; Wallace, 1974). Much new recent information has become available.


Polymorphonuclear Leukocyte Acute Gout Porphyria Cutanea Tarda Calcium Pyrophosphate Acute Gouty Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agudelo, C.A., Schumacher, H.R.: The synovitis of acute gouty arthritis: a light and electron microscopic study. Hum. Pathol. 4, 265–279 (1973)PubMedGoogle Scholar
  2. Alvan, G., Orme, M, Bertelsson, L., Ekstrand, R., Palmer, L.: Pharmacokinetics of indomethacin. Clin. Pharmacol. Ther. 18, 364–373 (1975)PubMedGoogle Scholar
  3. Alvares, A.P., Kapelner, S., Sassa, S., Kappas, A.: Drug metabolism in normal children, lead poisoned children, and normal adults. Clin. Pharmacol. Ther. 17, 179–186 (1975)PubMedGoogle Scholar
  4. Arreaza-Plaza, C.A., Bosch, V., Otayek, M.A.: Lipid transport across the intestinal epithelial cell: effect of colchicine. Biochim. Biophys. Acta (Amst.) 431, 297–302 (1976)Google Scholar
  5. Back, A., Walaszek, E.J.: Studies with radioactive colchicine. I. The influence of tumors on the tissue distribution of radioactive colchicine in mice. Cancer Res. 13, 552–555 (1953)PubMedGoogle Scholar
  6. Back, A., Walaszek, E.J., Uyeki, E.: Distribution of radioactive colchicine in some organs of normal and tumor-bearing mice. Proc. Soc. exp. Biol. (N.Y.) 77, 667–669 (1951)Google Scholar
  7. Benitez, H.H., Murray, M.R., Chargaff, E.: Antagonism between colchicine and tropolone in rat fibroblast cultures. Experientia (Basel) 9, 426–427 (1953)Google Scholar
  8. Benitez, H.H., Murray, M.R., Chargaff, E.: Studies of the inhibition of the colchicine effect on mitosis. Ann. N.Y. Acad. Sci. 58, 1288–1302 (1954)PubMedGoogle Scholar
  9. Berlin, R.D.: Temperature dependence of nucleoside membrane transport in rabbit alveolar macrophages and polymorphonuclear leukocytes. J. biol. Chem. 248, 4724–4730 (1973)PubMedGoogle Scholar
  10. Board, J.A.: Effects of colchicine on human ovulation. Amer. J. Obstet. Gynec. 89, 830–831 (1964)PubMedGoogle Scholar
  11. Boardman, P.L., Hart, F.D.: Side effects of indomethacin. Ann. Rheum. Dis. 26, 127–132 (1967)PubMedGoogle Scholar
  12. Borisy, G.G., Taylor, E.W.: The mechanism of action of colchicine. Binding of colchicine-H3 to cellular protein. J. Cell Biol. 34, 525–533 (1967)PubMedGoogle Scholar
  13. Boruchow, I.B.: Bone marrow depression associated with acute colchicine toxicity in the presence of hepatic dysfunction. Cancer 19, 541–543 (1966)PubMedGoogle Scholar
  14. Boudene, C., Duprey, F., Buohon, C.: Radioimmunoassay of colchicine. Biochem. J. 151, 413–415 (1975)PubMedGoogle Scholar
  15. Boyland, E., Mawson, E.H.: The conversion of colchicine into colchiceine. Biochem. J. 32, 1204–1206 (1938)PubMedGoogle Scholar
  16. Bremner, W.J., Paulsen, C.A.: Colchicine and testicular function in man. New Engl. J. Med. 294, 1384–1385(1976)PubMedGoogle Scholar
  17. Brodie, B.B.: Displacement of one drug by another from carrier or receptor sites. Proc. roy. Soc. Med. 58, 946–955 (1965)PubMedGoogle Scholar
  18. Brown, W.O., Seed, L.: Effect of colchicine on human tissues. Amer. J. Clin. Pathol. 15, 189–195 (1945)Google Scholar
  19. Brues, A.M.: The fate of colchicine in the body. J. clin. Invest. 21, 646 (1942)Google Scholar
  20. Brues, A.M.: Discussion of a paper by M. Levine. Ann. N.Y. Acad. Sci. 51, 1406–1408 (1951)Google Scholar
  21. Bruns, B.J.: Colchicine toxicity. Aust. Ann. Med. 17, 341–344 (1968)PubMedGoogle Scholar
  22. Burns, J.J., Rose, R.K., Chenkin, T., Goldman, A., Schulert, A., Brodie, B.B.: The physiologic disposition of phenylbutazone in man, and a method for its estimation in biologic material. J. Pharmacol. exp. Ther. 109, 346–357 (1953)PubMedGoogle Scholar
  23. Burns, J.J., Rose, R.K., Goodwin, S., Reichenthal, J., Horning, E.C., Brodie, B.B.: The metabolic fate of phenylbutazone in man. J. Pharmacol. exp. Ther. 113, 481–489 (1955)PubMedGoogle Scholar
  24. Caner, J.E.Z.: Colchicine inhibition of Chemotaxis. Arthr. and Rheum. 8, 757–761 (1965)Google Scholar
  25. Carr, A.A.: Colchicine toxicity. Arch. intern. Med. 115, 29–33 (1965)PubMedGoogle Scholar
  26. Cestari, A.N., Botelho Viera Filho, J.P., Yonenaga, Y., Magnelli, N., Imada, J.: A case of human reproductive abnormalities induced by colchicine treatment. Rev. Bras. Biol. 25, 253–256 (1965)Google Scholar
  27. Champion, G.D., Paulus, H.E., Mongan, E.: The effect of aspirin on serum indomethacin. Clin. Pharmacol. Ther. 13, 239–244 (1972)PubMedGoogle Scholar
  28. Chang, Y.-H., Gralla, E.J.: Suppression of urate crystal-induced canine joint inflammation by heterologous anti-polymorphonuclear leukocyte serum. Arthr. and Rheum. 11, 145–150 (1968)Google Scholar
  29. Chang, Y.-H., Malawista, S.E.: Mechanism of action of colchicine IV. Failure of non-leukopenic doses of colchicine to suppress urate crystal-induced canine joint inflammation. Inflammation 1, 143–150 (1976)Google Scholar
  30. Cohen, M., McNamara, H.: The effect of colchicine on guinea pig intestinal enzyme activity. Amer. J. dig. Dis. 15, 247–250 (1970)PubMedGoogle Scholar
  31. Conney, A.H.: Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19, 317–366 (1967)PubMedGoogle Scholar
  32. Cook, J.W., Loudon, J.D.: The tropolones. Quart. Rev. 5, 99–130 (1951)Google Scholar
  33. Copeman, W.S.C.: A Short History of the Gout and the Rheumatic Diseases. Berkeley-Los Angeles: University of California Press 1964Google Scholar
  34. Crabie, P., Pollet, J., Pebay-Peyroula, F.: Etude de l’hémostase au cours des intoxications aigues par la colchicine. Europ. J. Toxicol. Environ. Hyg. 3, 373–385 (1970)Google Scholar
  35. Cuq, P.: Experience française du traitment de la crise de goutte aigue par le Naproxen. Scand. J. Rheumatol. Suppl. 2, 64–68 (1973)PubMedGoogle Scholar
  36. Davies, D.S., Thorgeirsson, S.S.: Individual differences in plasma half-lives of lipid-soluble drugs in man. Acta Pharmacol. Toxicol. (Kbh.) 29, 181–190 (1971)Google Scholar
  37. Desager, J.P., Vanderbist, M., Harvengt, C.: Naproxen plasma levels in volunteers after single dose administration by oral and rectal routes. J. clin. Pharmacol. 16, 189–193 (1976)PubMedGoogle Scholar
  38. Dewar, M.J.S.: Structure of colchicine. Nature (Lond.) 155, 141–142 (1945)Google Scholar
  39. Dieterle, W., Faigle, J.W., Früh, F, Mory, H., Theobald, W., Alt, K.O., Richter, W.J.: Metabolism of phenylbutazone in man. Arzneimittel-Forsch. 26, 572–577 (1976)Google Scholar
  40. Donker, A.J.M., Arisz, L., Brentjens, J.R.H., Van den Hern, G.K., Hollemans, H.J.G.: Effect of indomethacin on kidney function and plasma renin activity in man. Nephron 17, 288–290 (1976)PubMedGoogle Scholar
  41. Duggan, D.E., Hogans, A.F., Kwan, K.C., McMahon, F.G.: The metabolism of indomethacin in man. J. Pharmacol. exp. Ther. 181, 563–575 (1972)PubMedGoogle Scholar
  42. Ehrlich, H.P., Ross, R., Bornstein, P.: Effect of microtubular agents and secretion of collagen, a biochemical and morphological study. J. Cell Biol. 62, 390–405 (1974)PubMedGoogle Scholar
  43. Eigsti, O.J., Dustin, P., Jr.: Colchicine in Agriculture, Medicine, Biology, and Chemistry. Ames, Iowa: Iowa State College Press 1955Google Scholar
  44. Ellwood, M.G., Robb, G.H.: Self-poisoning with colchicine. Postgrad. med. J. 47, 129–131 (1971)PubMedGoogle Scholar
  45. Emmerson, B.T.: Regimen of indocin therapy in acute gouty arthritis. Br. Med. J. 1967II, 272–274Google Scholar
  46. Emori, W., Paulus, H.E., Bluestone, R., Pearson, C.M.: The pharmacokinetics of indomethacin in serum. Clin. Pharmacol. Ther. 14, 134 (1973)Google Scholar
  47. Ertel, N.H., Mittler, J.C., Akgun, S., Wallace, S.L.: A radioimmunoassay for colchicine in plasma and urine. Science 193, 233–235 (1976)PubMedGoogle Scholar
  48. Ertel, N.H., Wallace, S.L.: Purification of colchicine, its photoisomers and some congeners by paper and thin-layer chromatography. Biochem. Med. 4, 181–192 (1970)PubMedGoogle Scholar
  49. Ertel, N.H., Wallace, S.L.: Measurement of colchicine in urine and peripheral leukocytes. Clin. Res. 19, 348 (1971)Google Scholar
  50. Faloon, W.W.: Drug production of intestinal malabsorption. N.Y. State J. Med. 70, 2189–2192 (1970)PubMedGoogle Scholar
  51. Faloon, W.W., Webb, D.I., Race, T.F.: Cholesterol lowering effect of colchicine. Ann. intern. Med. 66, 1058 (1966)Google Scholar
  52. Feigen, L.P., Klainen, E., Chapnick, B.M., Kadowitz, P.J.: The effect of indomethacin on renal function in pentobarbital anesthetized dogs. J. Pharmacol. exp. Ther. 198, 457–463 (1976)PubMedGoogle Scholar
  53. Ferreira, N.R., Buoniconti, A.: Trisomy after colchicine therapy. Lancet 1968II, 1304Google Scholar
  54. Ferreira, S.H., Moncada, S., Vane, J.R.: Indomethacin and aspirin abolish prostaglandin release from spleen. Nature (Lond.) [New Biol.] 231, 237–239 (1971)Google Scholar
  55. Fitzgerald, T.J.: Molecular features of colchicine associated with antimitotic activity and inhibition of tubulin polymerization. Biochem. Pharmacol. 25, 1383–1387 (1976)PubMedGoogle Scholar
  56. Fitzgerald, T.J., Williams, B., Uyeki, E.: Colchicine on sodium urate-induced paw swelling in mice: structure-activity relationships of colchicine derivatives. Proc. Soc. exp. Biol. (N.Y.) 136, 115–120 (1971)Google Scholar
  57. Fleischman, W., Price, H.G., Fleischman, S.K.: Fate of intraperitoneally administered colchicines in the golden hamster. Med. Pharmacol. Exp. 12, 172–176 (1965)Google Scholar
  58. Fleischman, W., Price, H.G., Fleischman, S.K.: Fate of intraperitoneally administered colchicines in the Mongolian gerbil. Med. Pharmacol. Exp. 17, 323–326 (1967)Google Scholar
  59. Fleischman, W., Price, H.G., Fleischman, S.K.: Pathways of excretion of colchicine in the golden hamster. Pharmacology 1, 48–52 (1968)Google Scholar
  60. Flower, R.J.: Drugs which inhibit prostaglandin synthesis. Pharmacol. Rev. 26, 33–67 (1974)PubMedGoogle Scholar
  61. Forbes, E.J.: Colchicine and related compounds part 14. Structure of B- and γ-lumicolchicine. J. chem. Soc. 3864–3870 (1955)Google Scholar
  62. Franke, W.W., Stadler, J., Krein, S.: Autoradiographic localization of colchicine-binding sites. Beitr. Pathol. 146, 289–291 (1972)PubMedGoogle Scholar
  63. Furcht, L.T., Scott, R.E.: Effect of vinblastine sulfate, colchicine and lumicolchicine on membranous organization of normal and transformed cells. Exp. Cell Res. 96, 271–282 (1975)PubMedGoogle Scholar
  64. Gaultier, M., Kaufer, A., Bismuth, C., Crabie, P., Fréjaville, J.-P.: Données actuelles sur l’intoxication aigue par la colchicine. Ann. Med. Interne 12 605–618 (1969)Google Scholar
  65. Glickman, R.M., Perretto, J.L., Kirsch, K.: Intestinal lipoprotein formation: effect of colchicine. Gastroenterology 70, 347–352 (1976)PubMedGoogle Scholar
  66. Goldfinger, S.E.: Treatment of gout. New Engl. J. Med. 285, 1303–1306 (1971)PubMedGoogle Scholar
  67. Grewe, R., Wolfe, W.: Umwandlung des Colchizins durch Sonnenlicht. Chem. Ber. 84, 621–625 (1951)Google Scholar
  68. Gruber, C.M.: Clinical pharmacology of fenoprofen, a review. J. Rheumatol. Suppl. 2, 8–17 (1976)Google Scholar
  69. Gutman, A.B, Dayton, P.G, Yü, T.-F, Berger, L., Chen, W., Sican, L.E., Burns, J.J.: A study of the inverse relationships between pKa and rate of renal excretion of phenylbutazone analogues in man and dog. Amer. J. Med. 29, 1017–1033 (1960)PubMedGoogle Scholar
  70. Hamberg, M.: Inhibition of prostaglandin synthesis in man. Biophys. Res. Commun. 49, 720–726 (1972)Google Scholar
  71. Harrison, I.T., Lewis, B., Nelson, P., Rooks, W., Roszkowski, A., Tomolonis, A., Fried, J.H.: Nonsteroidal anti-inflammatory agents. I. 6-substituted 2 naphylacetic acids. J. med. Chem. 13, 203–205 (1970)PubMedGoogle Scholar
  72. Hartung, E.F.: History of the use of Colchicum and related medicaments in gout. Ann. rheum. Dis. 13, 190–200 (1954)PubMedGoogle Scholar
  73. Hartung, E.F.: Historical considerations. Metabolism 6, 196–208 (1957)PubMedGoogle Scholar
  74. Heath, D.A., Palmer, J.S., Aurbach, G.D.: The hypocalcemic action of colchicine. Endocrinology 50, 1589–1593 (1972)Google Scholar
  75. Herbst, J.J., Hurwitz, R., Sunshine, P., Kretschmer, N.: The effect of colchicine on intestinal disac-charides: correlation with biochemical aspects of cellular renewal. J. clin. Invest. 49, 530–536 (1970)PubMedGoogle Scholar
  76. Hill, F.W.G.: Malabsorption in dogs induced with oral colchicine. Brit. Vet. J. 128, 372–378 (1972)Google Scholar
  77. Hirsimaki, G., Arstelo, A., Trump, B.F.: Autophagocytosis: in vitro induction by microtubule poisons. Exp. Cell Res. 92, 11–14 (1975)Google Scholar
  78. Ho, P.P.K., Easterman, M.A.: Fenoprofen inhibition of prostaglandin synthesis. Prostaglandins 6, 107–113(1974)Google Scholar
  79. Hucker, H.B., Zacchei, A.G., Cox, S.V., Brodie, D.A., Cantwell, N.H.R.: Studies on the absorption, distribution and excretion of indomethacin in various species. J. Pharmacol. exp. Ther. 153, 237–249 (1966)Google Scholar
  80. Hunter, A.L., Klaasen, C.D.: Biliary excretion of colchicine. J. Pharmacol. exp. Ther. 192, 605–617(1975)PubMedGoogle Scholar
  81. Hvidberg, E.F., Andreasen, P.B., Ranek, L.: Plasma half-life of phenylbutazone in patients with impaired liver function. Clin. Pharmacol. Ther. 15, 171–177 (1974)PubMedGoogle Scholar
  82. Kantor, T.G., Brown, R.: Test of non-specific anti-inflammatory activity of colchicine. Arthr. and Rheum. 9, 862 (1966)Google Scholar
  83. Kaplan, H.: Sarcoid arthritis with a response to colchicine. New Engl. J. Med. 263, 778–781 (1960)PubMedGoogle Scholar
  84. Kaplan, H.: Further experiences with colchicine in the treatment of sarcoid arthritis. New Engl. J. Med. 268, 761–764 (1963)Google Scholar
  85. Kontos, H.A.: Myopathy associated with chronic colchicine toxicity. New Engl. J. Med. 266, 38–39 (1962)PubMedGoogle Scholar
  86. Kuokkanen, K.: Porphyria cutanea tarda due to colchicine in a patient with gout. Acta Derm. Venereol. 51, 318–320 (1971)PubMedGoogle Scholar
  87. Lambert, D.T., Fingerman, M.: Evidence for a non-microtubular effect in pigment granule aggregation in melanophores of the fiddler crab, Uca pugilator. Comp. Biochem. Physiol. [C] 53, 25–28 (1976)Google Scholar
  88. Lettre, H.: Some investigations on cell behavior under various conditions. Cancer Res. 12, 847–860 (1952)PubMedGoogle Scholar
  89. Lettre, H., Lutze, M.: Beitrag zur Verteilung und Wirkung der Colchizine in Tierkörper. Z. physiol. Chem. 281, 58–64 (1944)Google Scholar
  90. Levi, A.J., Sherlock, S., Walker, D.: Phenylbutazone metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1968I, 1275–1279Google Scholar
  91. Lewis, R.J., Trager, W.F., Chan, K.K., Breckenridge, A., Orme, M., Roland, M., Schary, W.: Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J. clin. Invest. 53, 1607–1617 (1974)PubMedGoogle Scholar
  92. Lindquist, B., Jensen, K.M., Johansson, H., Hansen, T.: Effect of administration of aspirin and indomethacin on serum concentration. Clin. Pharmacol. Ther. 15, 247–252 (1974)PubMedGoogle Scholar
  93. Linskens, H.F., Wulf, W.: Über die Trennung und Mitosewirkung der Lumicolchicine. Naturwissenschaften 40, 487–488 (1953)Google Scholar
  94. Lockie, L.M.: A discussion of a therapeutic test and a provocative test in gouty arthritis. Ann. intern. Med. 13, 755–760 (1939)Google Scholar
  95. Loudon, J.D.: Chemistry of colchicine. In: Colchicine in Agriculture, Medicine, Biology, and Chemistry. Ames, Iowa: Iowa State College Press 1955Google Scholar
  96. Luketic, G.C., Shapiro, M.: Effect of colchicine on xylose absorption in dogs. Clin. Res. 11, 31 (1964)Google Scholar
  97. McCarty, D.J.: Calcium pyrophosphate crystal deposition disease-1975. Arthr. and Rheum. 19, 275–285 (1976)Google Scholar
  98. McLeod, J.G., Phillips, L.: Hypersensitivity to colchicine. Ann. rheum. Dis. 6, 224–229 (1947)Google Scholar
  99. Malawista, S.E.: Colchicine: a common mechanism for its anti-inflammatory and antimitotic effects. Arthr. and Rheum. 11, 191–197 (1968)Google Scholar
  100. Malawista, S.E.: The action of colchicine in acute gouty arthritis. Arthr. and Rheum. 18, 835–846 (1975)Google Scholar
  101. Malawista, S.E., Bensch, K.G.: Human polymorphonuclear leukocytes: demonstration of microtubules and effect of colchicine. Science 156, 521–522 (1967)PubMedGoogle Scholar
  102. Malawista, S.E., Chang, Y.-H., Wilson, L.: Lumicolchicine: lack of anti-inflammatory effect. Arthr. and Rheum. 15, 641–643 (1972)Google Scholar
  103. Margolis, L.: Colchicine-sensitive microtubules. Int. Rev. Cytol. 34, 333–361 (1973)Google Scholar
  104. Mason, R.W., McQueen, E.G.: Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate in vitro. Pharmacology 12, 12–19 (1974)PubMedGoogle Scholar
  105. Mauer, E.F.: The toxic effects of phenylbutazone. New Engl. J. Med. 253, 404–410 (1955)PubMedGoogle Scholar
  106. Merlin, H.E.: Azospermia caused by colchicine. Fertil. Steril. 23, 180–181 (1972)PubMedGoogle Scholar
  107. Millburn, P.: Factors in the biliary excretion of organic compounds. In: Metabolic Conjugation and Metabolic Hydrolysis, Vol. 2. New York: Academic Press 1970Google Scholar
  108. Mittler, J.C., Ertel, N.H., Akgun, S., Wallace, S.L.: A radioimmunoassay for colchicine in plasma and urine. Clin. Res. 23, 222 (1975)Google Scholar
  109. Mizel, S.B., Wilson, L.: Nucleoside transport in mammalian cells: inhibition by colchicine. Biochemistry 11, 2573–2578 (1972)PubMedGoogle Scholar
  110. Myren, J., Luketic, G.C., Ceballos, R., Sachs, G., Hirschowitz, B.I.: Effects of colchicine on intestinal mucosal disaccharidases. Amer. J. Dig. Dis. 11, 394–403 (1966)PubMedGoogle Scholar
  111. O’Brien, W.M.: Indomethacin: a survey of clinical trials. Clin. Pharmacol. Ther. 9, 94–107 (1968)PubMedGoogle Scholar
  112. Oliver, J.M., Ukena, T.E., Berlin, R.D.: Effects of phagocytosis and colchicine on the lectin-binding sites on cell surfaces. Proc. nat. Acad. Sci. (Wash.) 71, 394–398 (1974)Google Scholar
  113. Ortel, R.W., Newcombe, D.S.: Acute gouty arthritis and response to colchicine in the virtual absence of synovial fluid leukocytes. New Engl. J. Med. 290, 1363–1364 (1974)PubMedGoogle Scholar
  114. Pace-Asciak, C., Cole, S.: Inhibitors of prostaglandin catabolism. Experientia (Basel) 31, 143–145 (1975)Google Scholar
  115. Padawer, J.: Paramitotic effects of colchicine: further studies of the mast cell assay. Proc. Soc. exp. Biol. (N.Y.) 127, 194–199 (1968)Google Scholar
  116. Palmer, L., Bertilsson, L., Alvan, G, Orme, M., Sjogvist, F., Holmstedt, B.: Indomethacin: quantative determination in plasma by mass fragmentography, including pilot pharmaco-kinetics in man. In: Prostaglandin Synthetase Inhibitors. New York: Raven Press 1974Google Scholar
  117. Patak, R.V., Mookerjee, B.K., Bentzel, C.J., Hysert, P.E., Babej, M., Lee, J.B.: Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins 10, 649–659 (1975)PubMedGoogle Scholar
  118. Paulus, H.E., Schlosstein, L.H., Godfrey, R.G., Klinenberg, J.R., Bluestone, R.: Prophylactic colchicine therapy of intercritical gout. Arthr. and Rheum. 17, 609–614 (1974)Google Scholar
  119. Pelletier, P.J., Caventou, J.-B.: Examen chimique de plusiers vegetaux de la famille des colchicées et du principe actif qu’ils renferment. Ann. Chim. Phys. 14, 69–83 (1820)Google Scholar
  120. Perry, K., Jonen, H.G., Kahl, G.F., Jähnshen, E.: Elimination and distribution of phenylbutazone in rats during the course of adjuvant-induced arthritis. J. Pharmacol, exp. Ther. 197, 470–477 (1976)Google Scholar
  121. Pesanti, E.L., Axline, S.G.: Colchicine effects on lysosomal enzyme induction and intracellular degradation in the cultivated macrophage. J. exp. Med. 141, 1030–1046 (1975)PubMedGoogle Scholar
  122. Phelps, P.: Polymorphonuclear leukocyte motility in vitro. II. Stimulatory effect of monosodium urate crystals and urate in solution. Arthr. and Rheum. 12, 189–196 (1969)Google Scholar
  123. Phelps, P.: Appearance of chemotactic activity following intraarticular injection of monosodium urate crystals: effect of colchicine. J. Lab. clin. Med. 76, 622–631 (1970a)PubMedGoogle Scholar
  124. Phelps, P.: Polymorphonuclear leukocyte activity in vitro IV. Arthr. and Rheum. 13, 1–9 (1970b)Google Scholar
  125. Phelps, P., McCarty, D.J.: Crystal-induced inflammation in canine joints. II. Importance of polymorphonuclear leukocytes. J. exp. Med. 124, 115–126 (1966)PubMedGoogle Scholar
  126. Phelps, P., McCarty, D. J.: Crystal induced arthritis. Postgrad. med. 45, 87–93 (1969)PubMedGoogle Scholar
  127. Powell, H.C., Wolf, P.L.: Neutrophilic leukocyte inclusions in colchicine intoxication. Arch. Path. Lab. Med. 100, 136–138 (1976)PubMedGoogle Scholar
  128. Prescott, L.F.: Pharmocokinetic drug interactions. Lancet 1969II, 1239–1243Google Scholar
  129. Race, T.F., Paes, I.C., Faloon, W.W.: Intestinal malabsorption induced by oral colchicine. Amer. J. Med. Sci. 259, 32–41 (1970)PubMedGoogle Scholar
  130. Redman, C.M., Benerjee, D., Howell, K., Palade, G.E.: Colchicine inhibition of plasma protein release from rat hepatocytes. J. Cell Biol. 66, 42–59 (1975)PubMedGoogle Scholar
  131. Richter, W.J, Alt, K.O, Dieterle, W, Faigle, J.W, Kriemler, H.-P, Mory, H., Winkler, T.: C-glucuronides, a novel type of drug metabolite. Helv. chim. Acta 58, 2512–2517 (1975)PubMedGoogle Scholar
  132. Robinson, D.R, Levine, L.: Prostaglandin concentrations in synovial fluid in rheumatic diseases: action of indomethacin and aspirin. In: Prostaglandin Synthetase Inhibitors. New York: Raven Press 1974Google Scholar
  133. Roszkowski, A.P, Rooks, W.H, Tomolonis, A.J, Miller, L.M.: Anti-inflammatory and analgetic properties of d-2-(61-methoxy-21-naphthyl)-propionic acid (naproxen). J. Pharmacol. exp. Ther. 179, 114–123 (1971)PubMedGoogle Scholar
  134. Rubin, A, Chernish, S.M, Crabtree, R, Gruber, C.M., Helleberg, L., Rodda, B.E., Warrick, P., Wolen, R.L., Ridolfo, A.S.: A profile of the physiologic disposition and gastrointestinal effects of fenoprofen in man. Curr. Med. Res. Opin. 2, 529–544 (1974)PubMedGoogle Scholar
  135. Rubin, A., Rodda, B.E., Warrick, P., Ridolfo, A.S., Gruber, C.M.: Physiologic disposition of fenoprofen in man. II. Plasma and urine pharmacokinetics after oral and intravenous administration. J. Pharm. Sci. 61, 739–745 (1972)PubMedGoogle Scholar
  136. Rubulis, A., Rubert, M., Faloon, W.W.: Cholesterol lowering, fecal bile acid and sterol changes during neomycin and colchicine. J. clin. Nutr. 23, 1251–1259 (1970)Google Scholar
  137. Rumpf, K.W., Frenzel, S., Lowitz, H.D., Scheler, F.: The effect of indomethacin on plasma renin activity in man under normal conditions and after stimulation of the renin-angiotensin system. Prostaglandins 10, 641–648 (1975)PubMedGoogle Scholar
  138. Runkel, R., Forchielli, E., Boost, G., Chaplin, M., Hill, R., Sevelius, H., Thompson, G., Segre, E.: Naproxen metabolism, excretion and comparative pharmacokinetics. Scand. J. Rheumatol. Suppl. 2, 29–36 (1973)Google Scholar
  139. Sagorin, C., Ertel, N.H., Wallace, S.L.: Photoisomerization of colchicine. Loss of significant antimitotic activity in tissue culture. Arthr. and Rheum. 15, 213–217 (1972)Google Scholar
  140. Schary, W.L, Lewis, R.J, Rowland, M.: Warfarin-phenylbutazone interaction in man: a long-term multiple dose study. Res. Commun. Chem. Pathol. Pharmacol. 10, 663–672 (1975)PubMedGoogle Scholar
  141. Schoenharting, M, Mende, G, Siebert, G.: The metabolic transformation of colchicine. II. The metabolism of colchicine by mammalian liver microsomes. Hoppe-Seylers Z. physiol. Chem. 355, 1391–1399(1974)Google Scholar
  142. Schoenharting, M., Pfaender, P., Ricker, A, Siebert, G.: The metabolic transformation of colchicine. I. The oxidative formation of products from colchicine in the Udenfriend system. Hoppe-Seylers Z. physiol. Chem. 354, 421–436 (1973)Google Scholar
  143. Segre, E.J.: Naproxen metabolism in man. J. Clin. Pharmacol. 15, 316–323 (1975)PubMedGoogle Scholar
  144. Segre, E.J, Runkel, R., Chaplin, M., Sevelius, H., Forchielli, E.: Naproxen-aspirin interactions in man. Clin. Pharmacol. Ther. 15, 374–379 (1974)PubMedGoogle Scholar
  145. Sharma, J.N, Zeitlin, I.J., Brooks, P.M., Dick, W.C.: Raised plasma kininogen levels in rheumatoid arthritis. Response to indomethacin and relationship to clinical indices. Ann. rheum. Dis. 34, 464 (1975)PubMedGoogle Scholar
  146. Sjöhalin, I.S., Sjödin, T.: Binding of drugs to human serum albumin. Biochem. Pharmacol. 21, 3041–3052 (1972)Google Scholar
  147. Skeith, M.D., Simkin, P.A., Healey, L.A.: The renal excretion of indomethacin and its inhibition by probenecid. Clin. Pharmacol. Ther. 9, 89–93 (1968)PubMedGoogle Scholar
  148. Smyth, C.J.: Indomethacin—its rightful place in treatment. Ann. intern. Med. 72, 430–432 (1970)PubMedGoogle Scholar
  149. Smyth, C.J, Frank, L.S.: Treatment of acute gouty arthritis. Rheumatism. 18, 2–8 (1962)PubMedGoogle Scholar
  150. Solberg, C.O.: Influence of therapeutic concentrations of phenylbutazone on granulocyte function. Acta path, microbiol. scand. B83, 100–104 (1975)Google Scholar
  151. Solomon, H.M., Schrogie, J.J.: The effect of various drugs on the binding of warfarin-C14 to human albumin. Biochem. Pharmacol. 16, 1219–1226 (1967)PubMedGoogle Scholar
  152. Solomon, H.M., Schrogie, J.J., Williams, D.: The displacement of phenybutazone-14C and warfarin-14C from human albumin by various drugs and fatty acids. Biochem. Pharmacol. 17, 143–151(1968)PubMedGoogle Scholar
  153. Spilberg, I., Mandell, B., Wochner, R.D.: Studies in crystal induced chemotactic factor. J. Lab. clin. Med. 83, 56–63 (1974)PubMedGoogle Scholar
  154. Stadler, J., Franke, W.W.: Colchicine-binding proteins in chromatin and membranes. Nature (Lond.) New Biol. 237, 237–238 (1972)Google Scholar
  155. Stadler, J., Franke, W.W.: Characterization of the colchicine binding of membrane fractions from rat and mouse liver. J. Cell Biol. 60, 297–303 (1974)PubMedGoogle Scholar
  156. Stennerman, G.N., Hayashi, T.: Colchicine intoxication: a reappraisal of its pathology based on a study of three fatal cases. Hum. Pathol. 2, 321–332 (1971)Google Scholar
  157. Sczeklik, A., Gryglewski, R.J., Czerndawski-Mysik, G., Zmuda, A.: Aspirin-induced asthma. Hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation. J. Allergy Clin. Immunol. 58, 10–18 (1976)Google Scholar
  158. Thompson, G.R., Ting, Y.M., Riggs, G.A.: Calcific tendonitis and soft tissue calcification resembling gout. J. Amer. med. Ass. 203, 464–472 (1968)Google Scholar
  159. Tomlinson, R.V., Ringold, H., Quereshi, M.C., Forchielli, E.: Relationship between inhibition of prostaglandin synthesis and drug efficacy. Biochim. Biophys. Res. Commun. 45, 552–559 (1972)Google Scholar
  160. Ukena, T.D., Berlin, R.D.: Effect of colchicine and vinblastine on the topographical separation of membrane functions. J. exp. Med. 136, 1–7 (1972)PubMedGoogle Scholar
  161. Vane, J.R.: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (Lond.) New Biol. 231, 232–235 (1971)Google Scholar
  162. Van Petten, A.R., Feng, H., Withey, R.J., Littau, H.F.: The physiologic availability of solid dosage forms of phenylbutazone. J. Clin. Pharmacol. 11, 177–186 (1971)Google Scholar
  163. Vesell, E.S., Page, J.G.: Genetic control of drug levels in man: phenylbutazone. Science 159, 1479–1480(1968)PubMedGoogle Scholar
  164. Vesell, E.S., Passananti, G.T., Johnson, A.O.: Failure of indomethacin and warfarin to interact in normal human volunteers. J. Clin. Pharmacol. 15, 486–495 (1975)PubMedGoogle Scholar
  165. Walaszek, E.J., Kelsey, F.E., Geiling, E.M.K.: Biosynthesis and isolation of radioactive colchicine. Science 116, 225–227 (1952)PubMedGoogle Scholar
  166. Walaszek, E.J, Kocsis, J.J.: Excretion of 14C labelled colchicine. Fed. Proc. 15, 495 (1956)Google Scholar
  167. Walaszek, E.J., Kocsis, J.J., LeRoy, G.V., Geiling, E.M.K.: Studies on the excretion of radioactive colchicine. Arch. int. Pharmacodyn. Ther. 125, 371–382 (1960)Google Scholar
  168. Walaszek, E.J., LeRoy, G.V., Geiling, E.M.K.: Renal excretion of radioactive colchicine in patients with and without neoplastic disease. Fed. Proc. 13, 413 (1954)Google Scholar
  169. Waldi, D., Schnackerz, K., Munter, F.: Eine systematische Analyse von Alkaloiden auf Dünnschichtplatten. J. Chromatog. 6, 61–73 (1961)Google Scholar
  170. Wallace, S.L.: Colchicine analogues in the treatment of acute gout. Arthr. and Rheum. 2, 389–395 (1959)Google Scholar
  171. Wallace, S.L.: Colchicine: clinical pharmacology in acute gouty arthritis. Amer. J. Med. 30, 439–448 (1961)PubMedGoogle Scholar
  172. Wallace, S.L.: Mechanism of action of colchicine. Arthr. and Rheum. 8, 744–748 (1965)Google Scholar
  173. Wallace, S.L.: The treatment of gout. Arthr. and Rheum. 15, 317–323 (1972)Google Scholar
  174. Wallace, S.L.: Colchicum. The panacea. Bull. N.Y. Acad. Med. 40, 130–135 (1973)Google Scholar
  175. Wallace, S.L.: Colchicine. Semin. Arthr. and Rheum. 3, 369–381 (1974)Google Scholar
  176. Wallace, S.L.: Colchicine and new anti-inflammatory drugs in the treatment of acute gout. Arthr. and Rheum. 18, 847–850 (1975 a)Google Scholar
  177. Wallace, S.L.: Gout and hypertension. Arthr. and Rheum. 18, 721–725 (1975b)Google Scholar
  178. Wallace, S.L., Bernstein, D., Diamond, H.: Diagnostic value of the colchicine therapeutic trial. J. Amer. med. Ass. 199, 525–528 (1967)Google Scholar
  179. Wallace, S.L., Ertel, N.H.: Colchicine: current problems. Bull. rheum. Dis. 20, 582–587 (1969)PubMedGoogle Scholar
  180. Wallace, S.L., Ertel, N.H.: Plasma levels of colchicine after oral administration of a single dose. Metabolism 22, 749–753 (1973)PubMedGoogle Scholar
  181. Wallace, S.L., Omokoku, B., Ertel, N.H.: Colchicine plasma levels. Implications as to pharmacology and mechanism of action. Amer. J. Med. 48, 443–448 (1970)PubMedGoogle Scholar
  182. Wanasukapunt, S., Lertratanakul, Y., Rubenstein, H.M.: Effect of fenoprofen calcium on acute gouty arthritis. Arthr. and Rheum. 19, 933–935 (1976)Google Scholar
  183. Webb, D.I., Chodos, R.B., Maher, C.Q., Faloon, W.W.: Mechanism of vitamin B12 malabsorption in patients receiving colchicine. New Engl. J. Med. 279, 845–850 (1968)PubMedGoogle Scholar
  184. Weiner, M., Chenkin, T., Burns, J.J.: Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease. Amer. J. Med. Sci. 228, 36–39 (1954)PubMedGoogle Scholar
  185. Wildman, W.C., Pursey, B.A.: Colchicine and related compounds. In: The Alkaloids, Vol. II. New York: Academic Press 1968Google Scholar
  186. Willkens, R.F., Case, J.B.: Treatment of acute gout with naproxen. Scand. J. Rheumatol. Suppl. 2, 69–71 (1973)PubMedGoogle Scholar
  187. Willkens, R.F., Case, J.B., Huix, F.J.: The treatment of acute gout with naproxen. J. clin. Pharmacol. 15, 363–366 (1976)Google Scholar
  188. Wilson, L., Bryan, J.: Biochemical and pharmacologic properties of microtubules. In: Advances in Cell and Molecular Biology. New York: Academic Press 1974Google Scholar
  189. Wilson, L., Friedkin, M.: The biochemical events of mitosis. I. Synthesis and properties of colchicine labelled with tritium in its acetyl moiety. Biochemistry 5, 2463–2468 (1966)PubMedGoogle Scholar
  190. Wilson, L., Friedkin, M.: The biochemical events of mitosis. II. The in vivo and in vitro binding of colchicine in grasshopper embryos and its possible relation to the inhibition of mitosis. Biochemistry 6, 3126–3135 (1967)PubMedGoogle Scholar
  191. Woodward, R.B.: A total synthesis of colchicine. In: The Harvey Lectures, Series 59. New York-London: Academic Press 1967Google Scholar
  192. Wunderlich, F., Müller, R., Speth, V.: Direct evidence for a colchicine-induced impairment in the mobility of membrane components. Science 182, 1136–1138 (1973)PubMedGoogle Scholar
  193. Wyngaarden, J.B., Kelley, W.N.: Gout and Hyperuricemia. New York: Grune and Stratton 1976Google Scholar
  194. Yü, T.-F., Burns, J.J., Paton, B.C., Gutman, A.B., Brodie, B.B.: Phenylbutazone metabolites; antirheumatic, sodium-retaining, and uricosuric effects in man. J. Pharmacol. exp. Ther. 123, 63–69 (1958)PubMedGoogle Scholar
  195. Yü, T.-F., Gutman, A.B.: Efficacy of colchicine prophylaxis. Ann. intern. Med. 55, 179–192 (1961)PubMedGoogle Scholar
  196. Zweig, M.H., Maling, H.M., Webster, M.E.: Inhibition of sodium urate rat hind paw edema by colchicine derivatives. Correlation with antimitotic activity. J. Pharmacol. exp. Ther. 182, 344–350 (1972)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1978

Authors and Affiliations

  • S. L. Wallace
  • N. H. Ertel

There are no affiliations available

Personalised recommendations